A detailed history of Riversedge Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Riversedge Advisors, LLC holds 5,049 shares of BMY stock, worth $282,491. This represents 0.06% of its overall portfolio holdings.

Number of Shares
5,049
Holding current value
$282,491
% of portfolio
0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$39.66 - $51.75 $200,243 - $261,285
5,049 New
5,049 $261,000
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $9,979 - $11,315
208 Added 4.02%
5,388 $292,000
Q4 2023

Jan 17, 2024

SELL
$48.48 - $57.85 $24,773 - $29,561
-511 Reduced 8.98%
5,180 $265,000
Q3 2023

Oct 19, 2023

BUY
$57.89 - $64.73 $10,304 - $11,521
178 Added 3.23%
5,691 $330,000
Q2 2023

Jul 13, 2023

SELL
$63.71 - $70.74 $19,176 - $21,292
-301 Reduced 5.18%
5,513 $352,000
Q1 2023

Apr 18, 2023

SELL
$65.71 - $74.53 $25,889 - $29,364
-394 Reduced 6.35%
5,814 $402,000
Q4 2022

Jan 20, 2023

BUY
$68.48 - $81.09 $11,504 - $13,623
168 Added 2.78%
6,208 $0
Q2 2022

Jul 28, 2022

BUY
$72.62 - $79.98 $72 - $79
1 Added 0.02%
6,040 $465,000
Q3 2021

Oct 20, 2021

BUY
$59.17 - $69.31 $12,248 - $14,347
207 Added 3.55%
6,039 $357,000
Q1 2021

Apr 28, 2021

SELL
$59.34 - $66.74 $31,094 - $34,971
-524 Reduced 8.24%
5,832 $368,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $25,174 - $28,527
436 Added 7.36%
6,356 $394,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $229 - $254
4 Added 0.07%
5,920 $357,000
Q2 2020

Aug 03, 2020

BUY
$54.82 - $64.09 $324,315 - $379,156
5,916 New
5,916 $348,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Riversedge Advisors, LLC Portfolio

Follow Riversedge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Riversedge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Riversedge Advisors, LLC with notifications on news.